FLT3 and acute myeloid leukemia: Prominent among the mutations that characterize AML is the Fms-Like Tyrosine kinase 3-Internal Tandem Duplication (FLT3-ITD) mutation, which accounts for ~23% of AML cases, and is linked to a particularly poor prognosis [6–8].